Synced daily from ClinicalTrials.gov via AACT. Last sync: .
18 Vorasidenib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 15 indications (including Glioma & Low Grade Glioma of Brain) and 1,899 total planned enrollment. 4 Phase 3 Vorasidenib trials and 1 Phase 2 are listed. 9 Vorasidenib clinical trials are actively recruiting at 4 U.S. sites across 4 states. Most recent activity: NCT07215910 (Jan 2040).
Where to Participate: All Vorasidenib Trial Sites in the U.S. (4 sites across 4 states)
Every actively recruiting Vorasidenibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
VICTORIAA Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study)
Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants
A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study)
A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy Subjects
A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study)
Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants
P1
completed
28
Institut de Recherches Internationales Servier (I.R.I.S.)
A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy Subjects
18 Vorasidenib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants. 4 are marked completed.
Are Vorasidenib clinical trials recruiting in 2026?
Yes — 5 Vorasidenib trials are actively recruiting in 2026, with 4 U.S. sites across 4 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Vorasidenib being studied for?
Vorasidenib is being studied for Glioma, Low Grade Glioma of Brain, Diffuse Glioma, Disease Attributes, Glioma of Brain and 30 more. The trials are grouped by indication on this page.
What phase is Vorasidenib in?
Vorasidenib clinical trials span 4 Phase 3, 1 Phase 2, 7 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Vorasidenib clinical trials?
The lead sponsor across the most Vorasidenib trials is Institut de Recherches Internationales Servier, with 10 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Vorasidenibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.